Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aranesp Clear all

Conditions: Anemia, Cervix Neoplasms
Interventions: NESP - Novel Erythropoiesis Stimulating Protein; Drug
Lead sponsor: Mirhashemi, Ramin, M.D.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 78
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Hematologic Malignancies
Interventions: Darbepoetin alfa; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MDS (Myelodysplastic Syndrome)
Interventions: Luspatercept, Darbeopoetin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 161
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 36
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 31 more

Conditions: Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild
Interventions: Darbepoetin Alfa, Normal Saline; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Northridge, California

Conditions: Multiple Myeloma
Interventions: High-Dose Density Therapy; Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions: Darbepoetin, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 1 Hour to 24 Hours
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more

Conditions: Anaemia
Interventions: Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas

Conditions: Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Interventions: Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia
Interventions: Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more

Conditions: Anemia
Interventions: Mircera, Darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more

Conditions: Renal Anemia
Interventions: AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more

Conditions: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 219
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Azacitadine and Hematopoietic Growth Factors; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Anemia
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more

Conditions: Myelodysplastic Syndromes
Interventions: Canakinumab Injection, Darbepoetin Alfa; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Tampa, Florida • Atlanta, Georgia

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Kidney Disease, Blood Pressure, Anemia
Interventions: Darbepoetin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neoplasms, Anemia, Cancer
Interventions: epoetin alfa, darbepoetin alfa; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 76
States / cities: Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 208
States / cities: Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more

Search by objective public record fields.

Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Luspatercept + Darbepoetin in MDS

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Mild Encephalopathy in the Newborn Treated With Darbepoetin

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Mechanisms of EPO-induced Hypertension

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease